Anne-Renee Hartman, MD, was the acting CMO of GRAIL and previously Vice President of Clinical Development and Medical Affairs. While at GRAIL, she created the largest clinical genomics program to develop, validate and demonstrate clinical utility for a pan-cancer early detection blood test. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, where she led the development of several commercialized diagnostics in oncology. Anne-Renee was previously an Assistant Professor of Medicine at The Dana Farber Cancer Institute. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a BS in Molecular Biology from Princeton University, an MD from The University of Michigan and completed her residency in Internal Medicine at The University of Chicago.
Molecular profiling of oncology patients is being adopted across leading medical organizations. This session consists of a panel with leaders representing diverse medical organizations discussing their approaches and strategies of implementing molecular profiling in order to meet their internal patient and organizational goals.